Alx oncology reports third quarter 2023 financial results and provides corporate update

South san francisco, calif., nov. 13, 2023 (globe newswire) -- alx oncology holdings inc., (“alx oncology” or “the company”) (nasdaq: alxo), an immuno-oncology company developing therapies that block the cd47 immune checkpoint pathway, today reported financial results for the third quarter ended september 30, 2023, and provided a corporate update.

ALXO Ratings Summary

ALXO Quant Ranking